Neurofibromatosis type 2 and multiple sclerosis

Dario-Lucas Helbing; Michael Brodhun; Oliver Tiedge; Helen Morrison; Steffen K Rosahl

doi:10.1016/j.msard.2019.101890

Neurofibromatosis type 2 and multiple sclerosis

Mult Scler Relat Disord. 2020 Apr:39:101890. doi: 10.1016/j.msard.2019.101890. Epub 2019 Dec 9.

Authors

Dario-Lucas Helbing¹, Michael Brodhun², Oliver Tiedge³, Helen Morrison⁴, Steffen K Rosahl⁵

Affiliations

¹ Department of Neurosurgery, Helios Klinikum, Erfurt 99089, Germany; Leibniz Institute for Age Research, Fritz Lipmann Institute, Jena 07745, Germany; Faculty of Medicine, Friedrich-Schiller-University Jena, 07743, Jena, Germany. Electronic address: dario.helbing@leibniz-fli.de.
² Department of Pathology, Helios Klinikum, Erfurt 99089, Germany.
³ Department of Neurology, St. Georg Klinikum and MVZ, Eisenach 99817, Germany.
⁴ Leibniz Institute for Age Research, Fritz Lipmann Institute, Jena 07745, Germany.
⁵ Department of Neurosurgery, Helios Klinikum, Erfurt 99089, Germany. Electronic address: steffen.rosahl@helios-gesundheit.de.

PMID: 31862656
DOI: 10.1016/j.msard.2019.101890

Abstract

Comorbidity of neurofibromatosis type 2 (NF2) and multiple sclerosis (MS) has rarely been reported. Since immunological mechanisms have been implicated in Nf2, coexistence of the two entities may offer insights into schwannoma pathogenesis with respect to the impact of the immune system. We present the case of a woman with a de novo mutation in the NF2 gene who later developed MS. In addition, we found a significantly higher count of T cells in a laryngeal schwannoma of this patient as compared to a schwannoma removed from a NF2 patient without MS. This finding correlated with a higher growth rate in the case of NF+MS.

Keywords: Macrophages; Multiple sclerosis; Neurofibromatosis type 2; Schwannoma; T-cells.

Publication types

Case Reports